Price Target Update on Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) : The most positive equity analysts on Abbott Laboratories (NYSE:ABT) expects the shares to touch $50, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $47.55 with an expected fluctuation of $1.75 from the mean.

Other Equity analysts have also commented on the company shares. In a research note released to the investors, Jefferies maintains its rating on Abbott Laboratories (NYSE:ABT).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies raises the new price target from $44 per share to $45 per share. The rating by the firm was issued on June 14, 2016.

Abbott Laboratories (NYSE:ABT): stock turned positive on Thursday. Though the stock opened at $39.04, the bulls momentum made the stock top out at $39.63 level for the day. The stock recorded a low of $38.99 and closed the trading day at $39.63, in the green by 2.30%. The total traded volume for the day was 10,755,509. The stock had closed at $38.74 in the previous days trading.

The company shares have dropped -21.47% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $51.74 and the one year low was seen on Jan 28, 2016. The 50-Day Moving Average price is $38.26 and the 200 Day Moving Average price is recorded at $40.48. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Senior Vice President) of Abbott Laboratories, Watkin Jared had sold 552 shares worth of $20,772 in a transaction dated June 15, 2016. In this transaction, 552 shares were sold at $37.63 per share.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.